Spots Global Cancer Trial Database for hydroxyurea
Every month we try and update this database with for hydroxyurea cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) | NCT00290771 | Recurrent Gliob... | Imatinib tablet... Hydroxyurea cap... | 18 Years - | Novartis | |
| Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera | NCT01949805 | Polycythemia Ve... | Peg-P-IFN-alpha... Hydroxyurea | 18 Years - | AOP Orphan Pharmaceuticals AG | |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer | NCT00002951 | Esophageal Canc... Head and Neck C... | fluorouracil hydroxyurea surgical proced... radiation thera... | - | University of Chicago | |
| Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | NCT03860844 | Acute Lymphobla... Acute Myeloid L... | Isatuximab Dexamethasone o... Fludarabine Cytarabine Liposomal dauno... Daunorubicin (n... Idarubicin Filgrastim or e... Mitoxantrone Doxorubicin Vincristine Pegaspargase (P... Cyclophosphamid... Etoposide Methotrexate L - Asparginase Hydroxyurea L - Asparaginas... | 28 Days - 17 Years | Sanofi | |
| Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis | NCT04217356 | Myelofibrosis High-Risk Cance... Bone Marrow Can... | Hematopoietic s... Ruxolitinib Hydroxyurea | 18 Years - 70 Years | University Health Network, Toronto | |
| Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer | NCT00023959 | Metastatic Squa... Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Adeno... Stage III Basal... Stage III Esthe... Stage III Inver... Stage III Lymph... Stage III Lymph... Stage III Midli... Stage III Mucoe... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Adenoi... Stage IV Basal ... Stage IV Esthes... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Untreated Metas... | hydroxyurea fluorouracil bevacizumab radiation thera... filgrastim laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS | NCT00002940 | Lymphoma | hydroxyurea | - | St. Jude Children's Research Hospital | |
| Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS | NCT00002940 | Lymphoma | hydroxyurea | - | St. Jude Children's Research Hospital | |
| Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer | NCT03107182 | HPV-Related Squ... HNSCC | nab-paclitaxel Carboplatin Nivolumab Cisplatin Hydroxyurea 5-FU Dexamethasone Famotidine Diphenhydramine Paclitaxel Transoral robot... Adjuvant RT Chemoradiothera... | 18 Years - | University of Chicago | |
| Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors | NCT05853458 | Polycythemia Ve... | Hydroxyurea | 18 Years - 99 Years | Novartis | |
| Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) | NCT02252159 | MPN (Myeloproli... | 18 Years - | Incyte Corporation | ||
| Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002771 | Leukemia | recombinant int... busulfan cytarabine hydroxyurea idarubicin allogeneic bone... autologous bone... peripheral bloo... radiation thera... | - | National Cancer Institute (NCI) | |
| Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma | NCT00006119 | Brain and Centr... | hydroxyurea | 16 Years - 120 Years | UNICANCER | |
| Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients | NCT03515018 | Leukemia, Chron... | hydroxyurea Imatinib | 16 Years - | First Affiliated Hospital of Harbin Medical University | |
| Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002771 | Leukemia | recombinant int... busulfan cytarabine hydroxyurea idarubicin allogeneic bone... autologous bone... peripheral bloo... radiation thera... | - | National Cancer Institute (NCI) | |
| Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) | NCT01259856 | High Risk Polyc... High Risk Essen... | PEGASYS Hydroxyurea Aspirin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera | NCT05548062 | Polycythemia Ve... | Hydroxyurea Ruxolitinib | 18 Years - 99 Years | Novartis | |
| S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma | NCT00003590 | Adult Meningiom... | hydroxyurea | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera | NCT05548062 | Polycythemia Ve... | Hydroxyurea Ruxolitinib | 18 Years - 99 Years | Novartis | |
| Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | NCT00019474 | Extrahepatic Bi... Gastric Cancer Gastrointestina... Liver Cancer Pancreatic Canc... Small Intestine... | filgrastim recombinant int... fluorouracil hydroxyurea | 18 Years - 120 Years | Montefiore Medical Center | |
| Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus | NCT00008047 | Esophageal Canc... | fluorouracil hydroxyurea paclitaxel conventional su... radiation thera... | 18 Years - 80 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer | NCT00004901 | Head and Neck C... | ethynyluracil fluorouracil hydroxyurea radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | NCT00613054 | Glioblastoma Gliosarcoma | Zactima, Gleeve... | 18 Years - | Duke University | |
| Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma) | NCT03463733 | Glioma Glioblastoma | Hydroxyurea Temozolomide | - | Amsterdam UMC, location VUmc | |
| Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia | NCT00002869 | Leukemia | recombinant int... cytarabine hydroxyurea | - | National Cancer Institute (NCI) | |
| Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. | NCT02038036 | Polycythemia Ve... | Best Available ... Ruxolitinib | 18 Years - | Novartis | |
| Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) | NCT00615927 | Glioblastoma Gliosarcoma | Imatinib Mesyla... | 18 Years - | Duke University | |
| SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications | NCT04539678 | Thrombotic Pati... Diagnosis of My... Impact of Treat... | 18 Years - | Nantes University Hospital | ||
| Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. | NCT02038036 | Polycythemia Ve... | Best Available ... Ruxolitinib | 18 Years - | Novartis | |
| Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma | NCT00904735 | Brain and Centr... | hydroxyurea imatinib mesyla... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma | NCT00904735 | Brain and Centr... | hydroxyurea imatinib mesyla... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma | NCT00387933 | Brain and Centr... | hydroxyurea imatinib mesyla... vatalanib | 18 Years - | Duke University | |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx | NCT00004094 | Head and Neck C... | carboplatin fluorouracil hydroxyurea paclitaxel conventional su... radiation thera... | 15 Years - 80 Years | National Cancer Institute (NCI) | |
| Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma | NCT00154375 | Glioblastoma Mu... Astrocytoma | Imatinib mesyla... Hydroxyurea | 18 Years - 70 Years | Novartis | |
| Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004) | NCT02480608 | Leukemia, Myelo... | Imatinib Hydroxyurea | 18 Years - | University of Leipzig | |
| Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors | NCT00978146 | Desmoid Tumors Fibromatosis | Hydroxyurea | - 21 Years | Children's Hospital of Philadelphia | |
| Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004) | NCT02480608 | Leukemia, Myelo... | Imatinib Hydroxyurea | 18 Years - | University of Leipzig | |
| Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) | NCT00117572 | Cancer of the P... Cancer of the L... Cancer of the N... Paranasal Sinus... Cancer of the O... | docetaxel cisplatin hydroxyurea fluorouracil chemotherapy radiotherapy | 18 Years - | University of Chicago | |
| Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer | NCT02258659 | Human Papilloma... Stage III Squam... Stage IVA Squam... Stage IVB Squam... | paclitaxel albu... carboplatin radiation thera... paclitaxel fluorouracil hydroxyurea cisplatin laboratory biom... quality-of-life... | 18 Years - | University of Chicago | |
| Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT00055874 | Leukemia | recombinant int... cytarabine hydroxyurea imatinib mesyla... allogeneic bone... autologous bone... peripheral bloo... | 18 Years - 120 Years | Heidelberg University | |
| Combination of Hydroxyurea and Verapamil for Refractory Meningiomas | NCT00706810 | Cancer Brain Cancer Meningioma | Hydroxyurea Verapamil | 18 Years - | University of Utah | |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer | NCT01847326 | Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Tongue Cancer | carboplatin paclitaxel albu... fluorouracil hydroxyurea therapeutic con... radiation thera... hyperfractionat... laboratory biom... | 18 Years - | University of Chicago | |
| Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer | NCT00004897 | Esophageal Canc... | recombinant int... cisplatin fluorouracil hydroxyurea leucovorin calc... conventional su... radiation thera... | - | Northwestern University | |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer | NCT00004089 | Head and Neck C... | filgrastim fluorouracil hydroxyurea paclitaxel conventional su... radiation thera... | 15 Years - 80 Years | National Cancer Institute (NCI) | |
| PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE. | NCT00180973 | LOCALLY ADVANCE... | Hydroxyurea | 15 Years - 70 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) | NCT00117572 | Cancer of the P... Cancer of the L... Cancer of the N... Paranasal Sinus... Cancer of the O... | docetaxel cisplatin hydroxyurea fluorouracil chemotherapy radiotherapy | 18 Years - | University of Chicago | |
| Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors | NCT05853458 | Polycythemia Ve... | Hydroxyurea | 18 Years - 99 Years | Novartis | |
| AML Treatment in Untreated Adult Patients | NCT00449319 | Leukemia, Myelo... | Identification ... Daunorubicine Transplant | 15 Years - 61 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU | NCT05485948 | Polycythemia Ve... | Ropeginterferon... | 18 Years - | PharmaEssentia | |
| Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer | NCT01711541 | Head and Neck S... Stage IVA Oroph... Stage IVB Oroph... | Carboplatin Cisplatin Fluorouracil Hydroxyurea Laboratory Biom... Paclitaxel Placebo Adminis... Radiation Thera... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia | NCT00025402 | Leukemia | filgrastim recombinant int... busulfan cyclophosphamid... cytarabine etoposide hydroxyurea idarubicin allogeneic bone... peripheral bloo... radiation thera... | - | National Cancer Institute (NCI) | |
| Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer | NCT02258659 | Human Papilloma... Stage III Squam... Stage IVA Squam... Stage IVB Squam... | paclitaxel albu... carboplatin radiation thera... paclitaxel fluorouracil hydroxyurea cisplatin laboratory biom... quality-of-life... | 18 Years - | University of Chicago | |
| Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma) | NCT03463733 | Glioma Glioblastoma | Hydroxyurea Temozolomide | - | Amsterdam UMC, location VUmc | |
| Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | NCT00613054 | Glioblastoma Gliosarcoma | Zactima, Gleeve... | 18 Years - | Duke University | |
| Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer | NCT01711541 | Head and Neck S... Stage IVA Oroph... Stage IVB Oroph... | Carboplatin Cisplatin Fluorouracil Hydroxyurea Laboratory Biom... Paclitaxel Placebo Adminis... Radiation Thera... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy in Treating Patients With Glioblastoma | NCT00019058 | Brain and Centr... | chemotherapy hydroxyurea pentoxifylline radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| AML Treatment in Untreated Adult Patients | NCT00449319 | Leukemia, Myelo... | Identification ... Daunorubicine Transplant | 15 Years - 61 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma | NCT00387933 | Brain and Centr... | hydroxyurea imatinib mesyla... vatalanib | 18 Years - | Duke University | |
| Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | NCT00354913 | Glioblastoma Gliosarcoma | hydroxyurea imatinib mesyla... | 18 Years - | Duke University | |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer | NCT00004901 | Head and Neck C... | ethynyluracil fluorouracil hydroxyurea radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma | NCT00154375 | Glioblastoma Mu... Astrocytoma | Imatinib mesyla... Hydroxyurea | 18 Years - 70 Years | Novartis | |
| Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer | NCT00023959 | Metastatic Squa... Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Adeno... Stage III Basal... Stage III Esthe... Stage III Inver... Stage III Lymph... Stage III Lymph... Stage III Midli... Stage III Mucoe... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Adenoi... Stage IV Basal ... Stage IV Esthes... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Untreated Metas... | hydroxyurea fluorouracil bevacizumab radiation thera... filgrastim laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors | NCT01521299 | Advanced Solid ... | Hydroxyurea | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | NCT03860844 | Acute Lymphobla... Acute Myeloid L... | Isatuximab Dexamethasone o... Fludarabine Cytarabine Liposomal dauno... Daunorubicin (n... Idarubicin Filgrastim or e... Mitoxantrone Doxorubicin Vincristine Pegaspargase (P... Cyclophosphamid... Etoposide Methotrexate L - Asparginase Hydroxyurea L - Asparaginas... | 28 Days - 17 Years | Sanofi | |
| Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera | NCT01949805 | Polycythemia Ve... | Peg-P-IFN-alpha... Hydroxyurea | 18 Years - | AOP Orphan Pharmaceuticals AG | |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer | NCT00004901 | Head and Neck C... | ethynyluracil fluorouracil hydroxyurea radiation thera... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
